Postoperative Radiotherapy and Panitumumab in High-Risk Salivary Gland Malignancies

NCT01634880 · clinicaltrials.gov ↗

PHASE2

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Stopped Lack of accrual.

Conditions

Salivary Gland Malignancy

Interventions

DRUG: Postoperative Radiotherapy and Panitumumab

Sponsor

Athanassios Argiris

Collaborators

[object Object]
[object Object]